NSF, Contrast Agent Link to be Reviewed
November 30th, 2009 meg
FDA committees are planning to discuss the possible link between gadolinium-based contrast agents and nephrogenic systemic fibrosis, or NSF.
The FDA’s Cardiovascular and Renal Drugs Advisory Committee and Drug Safety and Risk Management Advisory Committee will meet to review data from gadolinium contrast manufacturers.
The ultimate goal is to provide the FDA with recommendations to minimize NSF risk and differentiate the risk of NSF between contrast products.
The recommendations should give guidance on labeling and other risk-reduction methods.
